Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

6825 ARTÍCULOS , VIENDO DEL 3796 AL 3810

Mutated tau, amyloid and neuroinflammation in Alzheimer disease-A brief review

Hung AS, Liang Y, Chow TC, Tang HC, Wu SL, Wai MS, Yew DT.

Prog Histochem Cytochem. 2016 May;51(1):1-8. doi: 10.1016/j.proghi.2016.01.001. Epub 2016 Jan 16.

Peripheral Blood Adipokines and Insulin Levels in Patients with Alzheimer's Disease: A Replication Study and Meta-Analysis

Ma J, Zhang W, Wang HF, Wang ZX, Jiang T, Tan MS, Yu JT, Tan L.

Curr Alzheimer Res. 2016;13(3):223-33. doi: 10.2174/156720501303160217111434.

Alzheimer's disease

Scheltens P, Blennow K, Breteler MM, de Strooper B, Frisoni GB, Salloway S, Van der Flier WM.

Lancet. 2016 Jul 30;388(10043):505-17. doi: 10.1016/S0140-6736(15)01124-1. Epub 2016 Feb 24.

Bridging Integrator 1 (BIN1) Genotypes Mediate Alzheimer's Disease Risk by Altering Neuronal Degeneration

Wang HF, Wan Y, Hao XK, Cao L, Zhu XC, Jiang T, Tan MS, Tan L, Zhang DQ, Tan L, Yu JT; Disease Neuroimaging Initiative Alzheimer’s.

J Alzheimers Dis. 2016 Mar 15;52(1):179-90. doi: 10.3233/JAD-150972.

Longitudinal relationships among biomarkers for Alzheimer disease in the Adult Children Study

Xiong C, Jasielec MS, Weng H, Fagan AM, Benzinger TL, Head D, Hassenstab J, Grant E, Sutphen CL, Buckles V, Moulder KL, Morris JC.

Neurology. 2016 Apr 19;86(16):1499-506. doi: 10.1212/WNL.0000000000002593. Epub 2016 Mar 23.

ADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trials

Wang J, Logovinsky V, Hendrix SB, Stanworth SH, Perdomo C, Xu L, Dhadda S, Do I, Rabe M, Luthman J, Cummings J, Satlin A.

J Neurol Neurosurg Psychiatry. 2016 Sep;87(9):993-9. doi: 10.1136/jnnp-2015-312383. Epub 2016 Mar 23.

Crowdsourced estimation of cognitive decline and resilience in Alzheimer's disease

Allen GI, Amoroso N, Anghel C, Balagurusamy V, Bare CJ, Beaton D, Bellotti R, Bennett DA, Boehme KL, Boutros PC, Caberlotto L, Caloian C, Campbell F, Chaibub Neto E, Chang YC, Chen B, Chen CY, Chien TY, Clark T, Das S, Davatzikos C, Deng J, Dillenberger D, Dobson RJ, Dong Q, Doshi J, Duma D, Errico R, Erus G, Everett E, Fardo DW, Friend SH, Fröhlich H, Gan J, St George-Hyslop P, Ghosh SS, Glaab E, Green RC, Guan Y, Hong MY, Huang C, Hwang J, Ibrahim J, Inglese P, Iyappan A, Jiang Q, Katsumata Y, Kauwe JS, Klein A, Kong D, Krause R, Lalonde E, Lauria M, Lee E, Lin X, Liu Z, Livingstone J, Logsdon BA, Lovestone S, Ma TW, Malhotra A, Mangravite LM, Maxwell TJ, Merrill E, Nagorski J, Namasivayam A, Narayan M, Naz M, Newhouse SJ, Norman TC, Nurtdinov RN, Oyang YJ, Pawitan Y, Peng S, Peters MA, Piccolo SR, Praveen P, Priami C, Sabelnykova VY, Senger P, Shen X, Simmons A, Sotiras A, Stolovitzky G, Tangaro S, Tateo A, Tung YA, Tustison NJ, Varol E, Vradenburg G, Weiner MW, Xiao G, Xie L, Xie Y, Xu J, Yang H, Zhan X, Zhou Y, Zhu F, Zhu H, et al.

Alzheimers Dement. 2016 Jun;12(6):645-53. doi: 10.1016/j.jalz.2016.02.006. Epub 2016 Apr 11.

PET biomarkers: Use of imaging techniques in Alzheimer disease and neurodegeneration clinical diagnosis

García-Ribas G, Arbizu J, Carrió I, Garrastachu P, Martinez-Lage P.

Neurologia. 2017 Jun;32(5):275-277. doi: 10.1016/j.nrl.2016.03.002. Epub 2016 May 5.

Biomarker Exposure-Response Analysis in Mild-To-Moderate Alzheimer's Disease Trials of Bapineuzumab

Russu A, Samtani MN, Xu S, Adedokun OJ, Lu M, Ito K, Corrigan B, Raje S, Liu E, Brashear HR, Styren S, Hu C.

J Alzheimers Dis. 2016 May 3;53(2):535-46. doi: 10.3233/JAD-151065.

The Role of Cerebrospinal Fluid Biomarkers in the Evolution of Diagnostic Criteria in Alzheimer's Disease: Shortcomings in Prodromal Diagnosis

Szalárdy L, Zádori D, Klivényi P, Vécsei L.

J Alzheimers Dis. 2016 May 7;53(2):373-92. doi: 10.3233/JAD-160037.

Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials

Vandenberghe R, Rinne JO, Boada M, Katayama S, Scheltens P, Vellas B, Tuchman M, Gass A, Fiebach JB, Hill D, Lobello K, Li D, McRae T, Lucas P, Evans I, Booth K, Luscan G, Wyman BT, Hua L, Yang L, Brashear HR, Black RS; Bapineuzumab 3000 and 3001 Clinical Study Investigators.

Alzheimers Res Ther. 2016 May 12;8(1):18. doi: 10.1186/s13195-016-0189-7.

Exploratory human PET study of the effectiveness of (11)C-ketoprofen methyl ester, a potential biomarker of neuroinflammatory processes in Alzheimer's disease

Ohnishi A, Senda M, Yamane T, Mikami T, Nishida H, Nishio T, Akamatsu G, Ikari Y, Kimoto S, Aita K, Sasaki M, Shinkawa H, Yamamoto Y, Shukuri M, Mawatari A, Doi H, Watanabe Y, Onoe H.

Nucl Med Biol. 2016 Jul;43(7):438-44. doi: 10.1016/j.nucmedbio.2016.04.005. Epub 2016 Apr 28.

Potential neuroimaging biomarkers of pathologic brain changes in Mild Cognitive Impairment and Alzheimer's disease: a systematic review

Ruan Q, D'Onofrio G, Sancarlo D, Bao Z, Greco A, Yu Z.

BMC Geriatr. 2016 May 16;16:104. doi: 10.1186/s12877-016-0281-7.

Quantitative MRI to understand Alzheimer's disease pathophysiology

Bozzali M, Serra L, Cercignani M.

Curr Opin Neurol. 2016 Aug;29(4):437-44. doi: 10.1097/WCO.0000000000000345.

Genome research in pre-dementia stages of Alzheimer's disease

Moreno-Grau S, Ruiz A.

Expert Rev Mol Med. 2016 May 30;18:e11. doi: 10.1017/erm.2016.12.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias